University of Erlangen-Nuremberg-ko ikertzaileekin lankidetzan egindako argitalpenak (28)

2023

  1. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database

    JAMA dermatology, Vol. 159, Núm. 8, pp. 837-847

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

    Rheumatology (United Kingdom), Vol. 59, Núm. 7, pp. 1684-1694

  3. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements

    The Lancet Rheumatology, Vol. 2, Núm. 2, pp. e71-e83

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study

    Rheumatology (United Kingdom), Vol. 57, Núm. 2, pp. 370-381

  2. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study

    Annals of the Rheumatic Diseases, Vol. 77, Núm. 4, pp. 563-570

  3. There is a need for new systemic sclerosis subset criteria. A content analytic approach

    Scandinavian Journal of Rheumatology, Vol. 47, Núm. 1, pp. 62-70

2017

  1. Treatment outcome in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study (ESOS)

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 7, pp. 1207-1218

  2. Update of EULAR recommendations for the treatment of systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 8, pp. 1327-1339

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: A 10-year longitudinal study from the EUSTAR database

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 7, pp. 1285-1292

  3. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study

    PLoS ONE, Vol. 11, Núm. 10

  4. Influence of TYK2 in systemic sclerosis susceptibility: A new locus in the IL-12 pathway

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 8, pp. 1521-1526

2015

  1. Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database

    Clinical and Experimental Rheumatology, Vol. 33, pp. 75-79

  2. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Identification of IL12RB1 as a Novel Systemic Sclerosis Susceptibility Locus

    Arthritis and Rheumatology

  3. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis

    American Journal of Human Genetics, Vol. 94, Núm. 1, pp. 47-61